Quectel Unveils High-Performance KCMA32S Zigbee & BLE Module for Smart Lighting, Building and Home Networks
16.7.2025 15:00:00 CEST | Business Wire | Press Release
Quectel Wireless Solutions, a global IoT solutions provider, has announced the launch of its latest high-performance MCU Zigbee and BLE module, the KCMA32S. This innovative module is designed to meet the growing demands of IoT applications, featuring advanced connectivity options and a compact form factor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716499223/en/
Quectel unveils high-performance KCMA32S Zigbee & BLE module for smart lighting, building and home networks
Powered by Silicon Labs’ ultra-low-power EFR32MG21 wireless SoC, the KCMA32S module supports Zigbee 3.0 and BLE 5.3, enabling multi-protocol coexistence for enhanced communication capabilities. It is powered by an ARM Cortex-M33 processor with a frequency of up to 80 MHz, ensuring efficient performance for a wide range of applications. The module offers flexible memory configurations to suit various applications, with options of 64 KB RAM and 768 KB flash memory, or 96 KB SRAM and 1024 KB flash memory, providing ample resources for developers to create robust solutions.
A key feature of the KCMA32S is its support for Zigbee/BLE mesh networking, which increases network scalability and node counts with mesh topology. This capability is particularly suitable for devices that enable many-to-many communications, such as smart lighting, smart buildings, and smart home wireless networks. Additionally, the module offers an enhanced security option, Secure Vault, which provides a higher level of IoT security.
“With the launch of the KCMA32S, we’re expanding the possibilities for compact, high-performance IoT solutions,” commented Delbert Sun, Vice General Manager, Product Division, Quectel Wireless Solutions. “This module brings together robust multi-protocol connectivity, advanced security features, and a compact form factor, empowering developers to create smarter, more scalable IoT devices across industries like smart lighting, building automation, and consumer electronics.”
With its ultra-compact size of 20.0 mm × 12.0 mm × 2.2 mm, the KCMA32S is designed in a LCC + LGA form factor, optimizing both size and cost for end-products. This versatility allows for compatibility with diverse designs, making it an ideal choice for various IoT applications.
The KCMA32S supports up to 20 GPIOs, which can be multiplexed for various interfaces, including I2C, UART, SPI, and I2S, in the QuecOpen SDK solution. It also boasts superior sensitivity of -104 dBm and a transmit power of up to +20 dBm, providing flexibility and versatility for a range of applications.
Key features of the KCMA32S include:
- Zigbee 3.0 and BLE 5.3 support with multi-protocol coexistence
- 64 KB RAM and 768 KB flash memory or 96 KB SRAM and 1024 KB flash memory (optional)
- Zigbee/BLE mesh networking capabilities
- 20 GPIOs for multiplexed interfaces including I2C, UART, SPI, and I2S functions in QuecOpen solution
- Operating temperature range of -40 °C to +85 °C
- Optional PCB antenna/RF coaxial connector/pin antenna interface
The KCMA32S module is set to revolutionize the way developers approach IoT solutions, providing a powerful, compact, and secure option for a variety of applications.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,800+ professionals sets the pace for innovation in cellular, GNSS, satellite and Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250716499223/en/
Contacts
Media: media@quectel.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom